{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T02:49:41Z","timestamp":1779158981832,"version":"3.51.4"},"reference-count":71,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1393,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1111\/j.1600-0404.2011.01602.x","type":"journal-article","created":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T02:01:25Z","timestamp":1320717685000},"page":"72-82","source":"Crossref","is-referenced-by-count":25,"special_numbering":"supplement s192","title":["Non-vision adverse events with vigabatrin therapy"],"prefix":"10.1155","volume":"124","author":[{"given":"S. D.","family":"Walker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"K\u00e4lvi\u00e4inen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,11,8]]},"reference":[{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00426770","article-title":"Effect of elevated brain GABA concentrations on the actions of bicuculline and picrotoxin in mice","volume":"54","author":"Schechter","year":"1977","journal-title":"Psychopharmacol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/0024-3205(81)90511-7","article-title":"Increased gamma-aminobutyric acid (GABA), homocarnosine and beta-alanine in cerebrospinal fluid of patients treated with gamma-vinyl-GABA (4-amino-hex-5-enoic acid)","volume":"28","author":"Grove","year":"1981","journal-title":"Life Sci"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01602.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0404.2011.01596.x","article-title":"Mechanism of action of vigabatrin: correcting misperceptions","volume":"124","author":"Ben-Menachem","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(84)92112-3","article-title":"Double-blind study of \u03b3-Vinyl GABA in patients with refractory epilepsy","volume":"1","author":"Rimmer","year":"1984","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1528-1157.1986.tb03512.x","article-title":"Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy","volume":"27","author":"Loiseau","year":"1986","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1528-1157.1986.tb03600.x","article-title":"Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study","volume":"27","author":"Tartara","year":"1986","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.410170307","article-title":"\u03b3-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy","volume":"17","author":"Gram","year":"1985","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1212\/WNL.37.2.184","article-title":"Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up","volume":"37","author":"Browne","year":"1987","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archneur.1987.00520210009010","article-title":"Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy","volume":"44","author":"Tassinari","year":"1987","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1528-1157.1993.tb02115.x","article-title":"Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?","volume":"34","author":"McKee","year":"1993","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/jnnp.57.9.1057","article-title":"Effects of vigabatrin on partial seizures and cognitive function","volume":"57","author":"Gr\u00fcnewald","year":"1994","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/WNL.46.1.54","article-title":"A double-blind, placebo-controlled study of vigabatrin three g\/day in patients with uncontrolled complex partial seizures","volume":"46","author":"French","year":"1996","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0920-1211(96)01006-6","article-title":"Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis","volume":"26","author":"Chiron","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1528-1157.1997.tb00063.x","article-title":"Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study","volume":"38","author":"Vigevano","year":"1997","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1528-1157.1999.tb01991.x","article-title":"Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures","volume":"40","author":"Dean","year":"1999","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1528-1157.1999.tb02049.x","article-title":"Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.57.8.1416","article-title":"Randomized trial of vigabatrin in patients with infantile spasms","volume":"57","author":"Elterman","year":"2001","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(04)17400-X","article-title":"The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14\u2003days: a multicentre, randomised controlled study","volume":"364","author":"Lux","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(05)70199-X","article-title":"The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to 14\u2003months: a multicentre randomised trial","volume":"4","author":"Lux","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/adc.2009.160606","article-title":"Developmental and epilepsy outcomes at age 4\u2003years in the UK infantile spasms trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial","volume":"95","author":"Darke","year":"2010","journal-title":"Arch Dis Child"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/0883073810365103","article-title":"Vigabatrin for the treatment of infantile spasms: final report of a randomized trial","volume":"25","author":"Elterman","year":"2010","journal-title":"J Child Neurol"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01602.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0404.2011.01597.x","article-title":"Vigabatrin therapy for refractory complex partial seizures: review of major European trials","volume":"124","author":"Ben-Menachem","year":"2011","journal-title":"Acta Neurol Scand"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01602.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0404.2011.01598.x","article-title":"Vigabatrin therapy for refractory complex partial seizures: review of major US trials","volume":"124","author":"Faught","year":"2011","journal-title":"Acta Neurol Scand"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01602.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0404.2011.01599.x","article-title":"Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing","volume":"124","author":"Carmant","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1528-1167.2008.01988.x","article-title":"Vigabatrin: 2008 update","volume":"50","author":"Willmore","year":"2009","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nurt.2006.11.008","article-title":"Vigabatrin","volume":"4","author":"Wheless","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.53.5.922","article-title":"Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects","volume":"53","author":"K\u00e4lvi\u00e4inen","year":"1999","journal-title":"Neurology"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01602.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0404.2011.01600.x","article-title":"Primer on visual field testing methods and related algorithms for patients treated with vigabatrin","volume":"124","author":"Sergott","year":"2011","journal-title":"Acta Neurol Scand"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01602.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0404.2011.01601.x","article-title":"Understanding and interpreting vision safety issues with vigabatrin therapy","volume":"124","author":"Plant","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB30|cit30","volume-title":"SABRIL\u00ae Tablets [prescribing information]","year":"2010"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/seiz.2000.0381","article-title":"Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study","volume":"9","author":"Bruni","year":"2000","journal-title":"Seizure"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.1992.tb05079.x","article-title":"Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy","volume":"86","author":"Tartara","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ncl.2009.08.005","article-title":"Hormonal aspects of epilepsy","volume":"27","author":"Pennell","year":"2009","journal-title":"Neurol Clin"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1586\/ern.11.58","article-title":"Sexual and reproductive dysfunction associated with antiepileptic drug use in men with epilepsy","volume":"11","author":"Calabr\u00f2","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00404-011-1936-4","article-title":"Epilepsy and menopause","volume":"284","author":"Erel","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1759720X11410769","article-title":"Antiepileptics and bone health","volume":"3","author":"Meier","year":"2011","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB37|cit37","volume-title":"SABRIL\u00ae Oral Solution [prescribing information]","year":"2010"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/019262338701500203","article-title":"A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats","volume":"15","author":"Butler","year":"1987","journal-title":"Toxicol Pathol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/019262339001800201","article-title":"Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor","volume":"18","author":"Gibson","year":"1990","journal-title":"Toxicol Pathol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1528-1157.2000.tb00134.x","article-title":"The potential for vigabatrin-induced intramyelinic edema in humans","volume":"41","author":"Cohen","year":"2000","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/019262339302100507","article-title":"Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor","volume":"21","author":"Yarrington","year":"1993","journal-title":"Toxicol Pathol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB42|cit42","article-title":"Oral toxicity of vigabatrin in immature rats: characterization of intramyelinic edema [published online ahead of print April 4, 2011]","author":"Walzer","journal-title":"Neurotoxicology"},{"issue":"Suppl 1","key":"10.1111\/j.1600-0404.2011.01602.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"53S","DOI":"10.1111\/j.1365-2125.1989.tb03462.x","article-title":"Effects of vigabatrin on evoked potentials in dogs","volume":"27","author":"Arezzo","year":"1989","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 5","key":"10.1111\/j.1600-0404.2011.01602.x-BIB44|cit44","first-page":"S13","article-title":"Effects of high-dose gamma-vinyl GABA (vigabatrin) administration on visual and somatosensory evoked potentials in dogs","volume":"33","author":"Schroeder","year":"1992","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0920-1211(94)90033-7","article-title":"Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging","volume":"18","author":"Jackson","year":"1994","journal-title":"Epilepsy Res"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1212\/WNL.44.10.1944","article-title":"MRI monitoring of vigabatrin-induced intramyelinic edema in dogs","volume":"44","author":"Weiss","year":"1994","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1528-1157.1995.tb01672.x","article-title":"Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain","volume":"36","author":"Peyster","year":"1995","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/syn.20038","article-title":"Development of vigabatrin-induced lesions in the rat brain studied by magnetic resonance imaging, histology, and immunocytochemistry","volume":"53","author":"Preece","year":"2004","journal-title":"Synapse"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB49|cit49","first-page":"S17","article-title":"Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy","volume":"2","author":"Cannon","year":"1991","journal-title":"J Child Neurol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0920-1211(87)90054-4","article-title":"Vigabatrin: no microvacuoles in a human brain","volume":"1","author":"Pedersen","year":"1987","journal-title":"Epilepsy Res"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0920-1211(92)90080-D","article-title":"Absence of cortical white matter changes in three patients undergoing long-term vigabatrin treatment","volume":"12","author":"Hammond","year":"1992","journal-title":"Epilepsy Res"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1528-1157.1993.tb02398.x","article-title":"Vigabatrin (gamma-vinyl-GABA): neuropathologic evaluation in five patients","volume":"34","author":"Sivenius","year":"1993","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1528-1167.2008.01728.x","article-title":"Cerebral MRI abnormalities associated with vigabatrin therapy","volume":"50","author":"Pearl","year":"2009","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1528-1167.2008.01896.x","article-title":"Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy","volume":"50","author":"Wheless","year":"2009","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1528-1167.2010.02564.x","article-title":"Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms","volume":"51","author":"Dracopoulos","year":"2010","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0883073808324219","article-title":"Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin","volume":"24","author":"Milh","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3174\/ajnr.A2224","article-title":"Abnormal axial diffusivity in the deep gray nuclei and dorsal brain stem in infantile spasm treated with vigabatrin","volume":"32","author":"Simao","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1177\/0883073809348796","article-title":"Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration","volume":"24","author":"Horton","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB59|cit59","article-title":"Medication neurotoxicity in children [published online ahead of print July 23, 2011]","author":"Iyer","journal-title":"Pediatr Radiol"},{"issue":"Suppl 1","key":"10.1111\/j.1600-0404.2011.01602.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1007\/s00247-010-1838-9","article-title":"Vigabatrin-associated diffusion MRI abnormalities in tuberous sclerosis","volume":"48","author":"Thapa","year":"2010","journal-title":"Pediatr Radiol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB61|cit61","first-page":"143","article-title":"Interictal psychoses of epilepsy","volume":"55","author":"Trimble","year":"1991","journal-title":"Adv Neurol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00002018-199615030-00001","article-title":"Anticonvulsant-induced psychiatric disorders. The role of forced normalisation","volume":"15","author":"Trimble","year":"1996","journal-title":"Drug Saf"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0920-1211(96)00026-5","article-title":"Acute psychological disorders in patients with epilepsy: a nation-wide study","volume":"25","author":"Cockerell","year":"1996","journal-title":"Epilepsy Res"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1528-1157.1995.tb00976.x","article-title":"Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life","volume":"36","author":"Dodrill","year":"1995","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archneur.1995.00540340081016","article-title":"Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study","volume":"52","author":"K\u00e4lvi\u00e4inen","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/jnnp.56.12.1271","article-title":"Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy","volume":"56","author":"Gillham","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/DHPS.S13070","article-title":"Suicidal behavior and antiepileptic drugs in epilepsy: analysis of the emerging evidence","volume":"3","author":"Mula","year":"2011","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB68|cit68","article-title":"Psychiatric symptomatologies and disorders related to epilepsy and antiepileptic medications [published online ahead of print May 28, 2011]","author":"Hamed","journal-title":"Expert Opin Drug Saf"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/jnnp.54.5.435","article-title":"Vigabatrin and psychosis","volume":"54","author":"Sander","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1212\/WNL.53.7.1503","article-title":"Psychiatric adverse events during vigabatrin therapy","volume":"53","author":"Levinson","year":"1999","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01602.x-BIB71|cit71","unstructured":"F ood and D rug A dministration Statistical review and evaluation. Epileptic drugs and suicidality http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4372b1-01-FDA.pdf"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0404.2011.01602.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0404.2011.01602.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T07:49:43Z","timestamp":1671522583000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0404.2011.01602.x"}},"subtitle":["Non-vision adverse events with vigabatrin therapy"],"short-title":[],"issued":{"date-parts":[[2011,11,8]]},"references-count":71,"URL":"https:\/\/doi.org\/10.1111\/j.1600-0404.2011.01602.x","relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11,8]]}}}